PPARG and lung carcinoma: Budman and Calabro have shown synergistic cytotoxic increases in a variety of cell lines (MCF-7, MCF-7/adr, and SK-BR-3 breast cancer; H460 lung cancer; SW480 and RT4 colon cancer; HT1197 bladder cancer) between irinotecan and the PPARγ ligand LY293111 at clinically attainable doses [6], prompting human studies with this drug combination.